08:06 AM EDT, 06/23/2025 (MT Newswires) -- Cidara Therapeutics ( CDTX ) said Monday that its phase 2b trial evaluating CD388, its long-acting antiviral for seasonal influenza prevention, met its primary and secondary endpoints.

The study showed that a single dose of CD388 provided 76.1% protection at 450 mg, 61.3% at 300 mg, and 57.7% at 150 mg against symptomatic influenza over 24 weeks.

CD388 was well tolerated with no adverse events observed, the company said.

Cidara said it has submitted an end-of-phase 2 meeting request to the US Food and Drug Administration to discuss plans for a phase 3 trial.

Cidara shares surged 83% in pre-market trading.